Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae256 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Marion Wobser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology and Skin Cancer Center, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, CD8-Positive T-Lymphocytes, Receptors, KIR3DL1, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) is a rare and indolent lymphoma entity. Although TLPD was first identified many years ago, the molecular pathogenesis is still not fully understood.
Objectives
In order to better understand the molecular pathogenesis of cutaneous acral CD8+ TLPD and to identify further discriminatory markers to differentiate this lymphoma subtype from other CD8+ cutaneous lymphomas, we analysed five cases of cutaneous acral CD8+ TLPD for putative molecular alterations.
Methods
Somatic alterations were assessed using whole-exome and targeted sequencing of paraffin-embedded tissue. Results were evaluated using immunohistochemical staining of respective relevant proteins. CD8+ cutaneous T-cell lymphomas (n = 12) served as control for KIR3DL1 staining.
Results
Copy number variation analysis revealed a homozygous deletion of the KIR3DL1 gene in two of the analysed cases. This resulted in loss of KIR3DL1 protein expression, which was observed in all cases of cutaneous acral CD8+ TLPD. In contrast, KIR3DL1 expression was more variable in other CD8+ cutaneous T-cell lymphomas with 50% of analysed cases (n = 12) found to be positive. In addition, one further case of acral CD8+ TLPD harboured a loss-of-function mutation in the PIK3R1 gene, presumably activating the phosphoinositide 3-kinase-AKT pathway.
Conclusions
Alterations of the KIR3DL1 gene may be of pathogenetic relevance for acral CD8+ TLPD. Loss of KIR3DL1 protein expression may support the diagnosis of this indolent lymphoma entity; however, this is not a subtype-specific discriminative feature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology and Skin Cancer Center, University Hospital Würzburg, Würzburg, Germany.
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
- Institute of Pathology, University of Würzburg, Würzburg, Germany.
- Pathology Practice, Ingolstadt, Germany.
ORCID-Profile: Marion Wobser
Zitieren
APA
Wobser, M., Appenzeller, S., Roth, S., Siedel, C., Goebeler, M., Geissinger, E., Rosenwald, A., & Maurus, K. (2024). Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae256
Vancouver
Wobser M, Appenzeller S, Roth S, Siedel C, Goebeler M, Geissinger E, et al. Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae256
BibTeX
@article{Wobser2024,
author = {Wobser, Marion and Appenzeller, Silke and Roth, Sabine and Siedel, Claudia and Goebeler, Matthias and Geissinger, Eva and Rosenwald, Andreas and Maurus, Katja},
title = {Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae256}
}
EUVIMED